



Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

April 5, 2021

20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 10:15 am ET

Chardon 5th Annual Manufacturing Summit on Monday, April 26, 2021 at 1:00 pm ET

DALLAS--(BUSINESS WIRE)--Apr. 5, 2021-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the 20th Annual Needham Virtual Healthcare Conference and the Chardon 5th Annual Manufacturing Summit.

Conferences Details:

Event: 20th Annual Needham Virtual Healthcare Conference
Date: Monday, April 12, 2021
Time: 10:15 am ET
Format: Fireside chat
Participants: RA Session II, President, Founder and CEO

Event: Chardon 5th Annual Manufacturing Summit
Date: Monday, April 26, 2021
Time: 1:00 pm ET
Format: Fireside chat
Participants: RA Session II, President, Founder and CEO
Fred Porter, Ph.D., Chief Technical Officer
Greg Gara, Senior Vice President of Manufacturing

Webcasts for these conferences will be available in the "Events & Media" section of the Taysha corporate website at <https://ir.tayshagtx.com/news-events/events-presentations>. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team's proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients' lives. More information is available at www.tayshagtx.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210405005218/en/): <https://www.businesswire.com/news/home/20210405005218/en/>

Company Contact:

Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:

Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.